Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation

FEBS Letters

Volumn 579, Issue 2, 2005, Pages 379-384

  Tachedjian, Gilda ^a,b,c   Moore, Katie L ^a   Goff, Stephen P ^d   Sluis Cremer, Nicolas ^e  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d Howard Hughes Medical Institute   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Efavirenz; Gag Pol processing; Human immunodeficiency virus type 1; NNRTI; Reverse transcriptase dimerization

Indexed keywords

EFAVIRENZ; NEVIRAPINE; POLYPROTEIN; PROTEIN; PROTEIN P51; PROTEIN P66; PROTEIN PRECURSOR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ACCELERATION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIMERIZATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 11844282799     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2004.11.099     Document Type: Article

References (37)

1. F. di Marzo Veronese, T.D. Copeland, A.L. DeVico, R. Rahman, S. Oroszlan, R.C. Gallo, and M.G. Sarngadharan Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV Science 231 1986 1289 1291
2. L.A. Kohlstaedt, J. Wang, J.M. Friedman, P.A. Rice, and T.A. Steitz Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor Science 256 1992 1783 1790
3. A. Jacobo-Molina Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA Proc. Natl. Acad. Sci. USA 90 1993 6320 6324
4. Z. Hostomsky, Z. Hostomska, T.B. Fu, and J. Taylor Reverse transcriptase of human immunodeficiency virus type 1: functionality of subunits of the heterodimer in DNA synthesis J. Virol. 66 1992 3179 3182
5. J. Wang, S.J. Smerdon, J. Jager, L.A. Kohlstaedt, P.A. Rice, J.M. Friedman, and T.A. Steitz Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer Proc. Natl. Acad. Sci. USA 91 1994 7242 7246
6. S.F. Le Grice, T. Naas, B. Wohlgensinger, and O. Schatz Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase EMBO J. 10 1991 3905 3911
7. R.J. Gorelick, and L.E. Henderson G. Myers B. Korber S. Wain-Hobson K.-T. Jeang L. Henderson G. Pavalakis Human Retroviruses and AIDS Analyses III 1994 The Los Alamos National Laboratory Los Alamos, NM 2 5
8. V.M. Vogt Proteolytic processing and particle maturation Curr. Top. Microbiol. Immunol. 214 1996 95 121
9. A.H. Kaplan, M. Manchester, and R. Swanstrom The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency J. Virol. 68 1994 6782 6786
10. H. Lindhofer, K. von der Helm, and H. Nitschko In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes Virology 214 1995 624 627
11. S.C. Pettit, S. Gulnik, L. Everitt, and A.H. Kaplan The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage J. Virol. 77 2003 366 374
12. J.M. Louis, F. Dyda, N.T. Nashed, A.R. Kimmel, and D.R. Davies Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease Biochemistry 37 1998 2105 2110
13. N. Almog, R. Roller, G. Arad, L. Passi-Even, M.A. Wainberg, and M. Kotler A p6Pol-protease fusion protein is present in mature particles of human immunodeficiency virus type 1 J. Virol. 70 1996 7228 7232
14. J.M. Louis, R.A. McDonald, N.T. Nashed, E.M. Wondrak, D.M. Jerina, S. Oroszlan, and P.T. Mora Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli Eur. J. Biochem. 199 1991 361 369
15. E.M. Wondrak, N.T. Nashed, M.T. Haber, D.M. Jerina, and J.M. Louis A transient precursor of the HIV-1 protease. Isolation, characterization, and kinetics of maturation J. Biol. Chem. 271 1996 4477 4481
16. N. Sluis-Cremer, D. Arion, M.E. Abram, and M.A. Parniak Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation Int. J. Biochem. Cell. Biol. 36 2004 1836 1847
17. E. De Clercq The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection Antiviral Res. 38 1998 153 179
18. O.S. Pedersen, and E.B. Pedersen Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom Antiviral Chem. Chemother. 10 1999 285 314
19. G. Tachedjian, and S.P. Goff The effect of NNRTIs on HIV reverse transcriptase dimerization Curr. Opin. Invest. Drugs 4 2003 966 973
20. S.J. Smerdon, J. Jager, J. Wang, L.A. Kohlstaedt, A.J. Chirino, J.M. Friedman, P.A. Rice, and T.A. Steitz Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1 Proc. Natl. Acad. Sci USA 91 1994 3911 3915
21. C. Tantillo Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance J. Mol. Biol. 243 1994 369 387
22. G. Tachedjian, M. Orlova, S.G. Sarafianos, E. Arnold, and S.P. Goff Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase Proc. Natl. Acad. Sci. USA 98 2001 7188 7193
23. A.M. Szilvay, S. Nornes, I.R. Haugan, L. Olsen, V.R. Prasad, C. Endresen, S.P. Goff, and D.E. Helland Epitope mapping of HIV-1 reverse transcriptase with monoclonal antibodies that inhibit polymerase and RNase H activities J. Acquir. Immune Defic. Syndr. 5 1992 647 657
24. B.M. Nilsen, I.R. Haugan, K. Berg, L. Olsen, P.O. Brown, and D.E. Helland Monoclonal antibodies against human immunodeficiency virus type 1 integrase: epitope mapping and differential effects on integrase activities in vitro J. Virol. 70 1996 1580 1587
25. G. Tachedjian, H.E. Aronson, and S.P. Goff Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase Proc. Natl. Acad. Sci. USA 97 2000 6334 6349
26. P.S. Jacques, B.M. Wohrl, K.J. Howard, and S.F. Le Grice Modulation of HIV-1 reverse transcriptase function in "selectively deleted" p66/p51 heterodimers J. Biol. Chem. 269 1994 1388 1393
27. S.F. Le Grice, and F. Gruninger-Leitch Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography Eur. J. Biochem. 187 1990 307 314
28. M.D. Rose, F. Winston, and P. Hieter Methods in Yeast Genetics, a Laboratory Course Manual 1990 Cold Spring Harbor Laboratory Press New York
29. G. Tachedjian, H.E. Aronson, M. de los Santos, J. Seehra, J.M. McCoy, and S.P. Goff Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization J. Mol. Biol. 326 2003 381 396
30. S.F. Le Grice, C.E. Cameron, and S.J. Benkovic Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase Methods Enzymol. 262 1995 130 144
31. T. Restle, B. Muller, and R.S. Goody Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention J. Biol. Chem. 265 1990 8986 8988
32. G. Divita, K. Rittinger, T. Restle, U. Immendorfer, and R.S. Goody Conformational stability of dimeric HIV-1 and HIV-2 reverse transcriptases Biochemistry 34 1995 16337 16346
33. N. Sluis-Cremer, G.I. Dmitrienko, J. Balzarini, M.J. Camarasa, and M.A. Parniak Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4″-amino-2″,2″-dioxo-1″, 2″-oxathiole-5″,3′-[2′,5′-bis-O-(tert- butyldimethylsilyl)-β-d-ribofuranosyl]]]-3-ethylthymine Biochemistry 39 2000 1427 1433
34. A.H. Kaplan, and R. Swanstrom Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments Proc. Natl. Acad. Sci. USA 88 1991 4528 4532
35. J. Park, and C.D. Morrow Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production J. Virol. 65 1991 5111 5117
36. V. Karacostas, E.J. Wolffe, K. Nagashima, M.A. Gonda, and B. Moss Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles Virology 193 1993 661 671
37. H.G. Krausslich Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles Proc. Natl. Acad. Sci. USA 88 1991 3213 3217